Leggett action continues
Tuesday, 16 September, 2008
Legal action against former Agenix CEO Neil Leggett is set to re-commence before the Supreme Court of Victoria on September 26.
Agenix [ASX: AGX] is taking action against Leggett, a former CEO, CFO and company secretary, alleging financial irregularities involving $3.865 million.
Agenix alleges that improper transactions occurred between it and a trustee company of Leggett’s family trust.
A stay of proceedings was ordered on September 12 as the trustee company has been placed into a creditor’s voluntary liquidation.
Leggett was with the company between 2003 and May 2008.
Agenix has been hit with further problems recently, with an intended acquisition in China stalling and two directors and the company chairman resigning in August.
It recently received a patent for its ThromboView technology in New Zealand. ThromboView is a humanised D-dimer antibody diagnostic with a range of imaging and therapeutic applications.
It is currently in Phase II trials in Canada and the US for the detection of pulmonary embolism.
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
